IP Library › Granted Patent US 12,398,213
Granted Patent B2
US 12,398,213 · App. 17/551,908 · Granted Aug 26, 2025

Methods of treating IL1RAP associated cancers with anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies

Inventors: Helena Ågerstam (Lund, SE); Thoas Fioretos (Lund, SE); Marcus Järås (Lund, SE); Cecilia Ann-Christin Malmborg Hager (Helsingborg, SE); Kjell Sjöström (Lund, SE); Agneta Svedberg (Lund, SE); Karin Von Wachenfeldt (Lund, SE)
Assignee: Cantargia AB
C07K16/2866C07K16/30C07K16/3015C07K16/3023C07K16/303C07K16/3038C07K16/3053C07K16/3069G01N33/57492A61K2039/505C07K2317/24C07K2317/32C07K2317/33C07K2317/41C07K2317/55C07K2317/56C07K2317/565C07K2317/72C07K2317/732C07K2317/76C07K2317/77C07K2317/92G01N2333/7155
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,398,213
App. No.
17/551,908
Granted
Aug 26, 2025
Kind
B2
Abstract

The present invention provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (IL1RAP) wherein the antibody or antigen-binding fragment is capable of inhibiting the binding of antibody ‘CAN04’ to human IL1RAP. The invention further provides the use of such antibodies or an antigen-binding fragments in the treatment and/or diagnosis of IL-1 associated diseases and conditions, including cancers such as acute myeloid leukemia and melanoma.

Claims (45)

1. A method for the treatment of a neoplastic disorder in a subject, comprising administering to a subject (a) a therapeutically effective amount of an antibody or antigen-binding fragment that has binding specificity for human interleukin-1 receptor accessory protein (IL1RAP), and (b) one or more further therapeutic agents, wherein the neoplastic disorder is associated with cells expressing IL1RAP, wherein the one or more further therapeutic agents are chemotherapeutic and/or immunotherapeutic agents, and wherein the antibody or antigen-binding fragment comprises:

a. A heavy chain variable region (VH) comprising (i) heavy chain CDR1 comprising GYAFTSS (amino acids 26-32 of SEQ ID NO:9); (ii) heavy chain CDR2 comprising YPGDGN (SEQ ID NO:4); and (iii) heavy chain CDR3 comprising GYLDPMDY (SEQ ID NO: 5); and a light chain variable region (VL) comprising (i) light chain CDR 1 comprising ASQGINNYLN (amino acids 25-34 of SEQ ID NO:16); (ii) light chain CDR2 comprising YTSGLHA (SEQ ID NO: 13); and (iii) light chain CDR3 comprising QQYSILPWT (SEQ ID NO: 14);

b A heavy chain variable region (VH) comprising (i) heavy chain CDR1 comprising GYAFTSS (amino acids 26-32 of SEQ ID NO:9); (ii) heavy chain CDR2 comprising YPGDGN (SEQ ID NO: 4); and (iii) heavy chain CDR3 comprising GYLDPMDY (SEQ ID NO: 5); and a light chain variable region (VL) comprising (i) light chain CDR 1 comprising SASQGINNYLN (SEQ ID NO:12); light chain CDR2 comprising YTSGLHA (SEQ ID NO: 13); and (iii) light chain CDR3 comprising QQYSILPWT (SEQ ID NO: 14);

c. A heavy chain variable region (VH) comprising (i) heavy chain CDR1 comprising GYAFSSS (SEQ ID NO:3); (ii) heavy chain CDR2 comprising YPGDGN (SEQ ID NO: 4); and (iii) heavy chain CDR3 comprising GYLDPMDY (SEQ ID NO: 5); and a light chain variable region (VL) comprising (i) light chain CDR 1 comprising SASQGINNYLN (SEQ ID NO:12); light chain CDR2 comprising YTSGLHA (SEQ ID NO: 13); and (iii) light chain CDR3 comprising QQYSILPWT (SEQ ID NO: 14);

d. A heavy chain variable region (VH) comprising (i) heavy chain CDR1 comprising GYAFSSS (SEQ ID NO: 3); (ii) heavy chain CDR2 comprising YPGDGN (SEQ ID NO: 4); and (iii) heavy chain CDR3 comprising GYLDPMDY (SEQ ID NO: 5); and a light chain variable region (VL) comprising (i) light chain CDR 1 comprising ASQGINNYLN (amino acids 25-34 of SEQ ID NO: 16); light chain CDR2 comprising YTSGLHA (SEQ ID NO: 13); and (iii) light chain CDR3 comprising QQYSILPWT (SEQ ID NO: 14);

e. A heavy chain variable region (VH) comprising (i) heavy chain CDR1 comprising GYTFTSS (amino acids 26-32 of SEQ ID NO: 10); (ii) heavy chain CDR2 comprising YPGDGQ (amino acids 52-57 of SEQ ID NO: 10); and (iii) heavy chain CDR3 comprising GYLDPMDY (SEQ ID NO: 5); and a light chain variable region (VL) comprising (i) light chain CDR 1 comprising SASQGINNYLN (SEQ ID NO: 12); light chain CDR2 comprising YTSGLHA (SEQ ID NO: 13); and (iii) light chain CDR3 comprising QQYSILPWT (SEQ ID NO: 14); or

f. A heavy chain variable region (VH) comprising (i) heavy chain CDR1 comprising GYTFTSS (amino acids 26-32 of SEQ ID NO: 10); (ii) heavy chain CDR2 comprising YPGDGQ (amino acids 52-57 of SEQ ID NO: 10); and (iii) heavy chain CDR3 comprising GYLDPMDY (SEQ ID NO: 5); and a light chain variable region (VL) comprising (i) light chain CDR 1 comprising ASQGINNYLN (amino acids 25-34 of SEQ ID NO: 16); light chain CDR2 comprising YTSGLHA (SEQ ID NO: 13); and (iii) light chain CDR3 comprising QQYSILPWT (SEQ ID NO: 14).

2. The method of claim 1 , wherein the neoplastic disorder is a neoplastic hematologic disorder.

3. The method of claim 2 , wherein the neoplastic hematologic disorder is selected from chronic myeloid leukemia (CML), myeloproliferative disorders (MPD), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).

4. The method of claim 1 , wherein the neoplastic disorder is associated with the formation of solid tumors within the subject's body.

5. The method of claim 1 , wherein the neoplastic disorder is selected from pancreatic cancer, lung cancer, breast cancer, head/neck cancer, melanomas, biliary tract cancer, colorectal cancer, bladder cancer, prostate cancer, brain/CNS cancer, cervical cancer, oesophageal cancer, gastric cancer, kidney cancer, liver cancer, lymphomas, ovarian cancer, and sarcomas.

6. The method of claim 1 , wherein the neoplastic disorder is selected from pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), non-squamous NSCLC, squamous NSCLC, and triple-negative breast cancer (TNBC).

7. The method of claim 1 , wherein the one or more further therapeutic agents are selected from platinum compounds, antimetabolites, alkylating agents, anthracyclines and other cytotoxic antibiotics, vinca alkyloids, etoposide, taxanes, topoisomerase I inhibitors, antiproliferative immunosuppressants, corticosteroids, sex hormones and hormone antagonists, and other therapeutic antibodies.

8. The method of claim 1 , wherein the neoplastic disorder is pancreatic cancer, and wherein the one or more further therapeutic agents are selected from gemcitabine and nab-paclitaxel; and folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX).

9. The method of claim 1 , wherein the neoplastic disorder is lung cancer, and wherein the one or more further therapeutic agents are selected from gemcitabine and cisplatin; carboplatin and pemetrexed; carboplatin and pemetrexed and pembrolizumab; and docetaxel.

10. The method of claim 1 , wherein the neoplastic disorder is breast cancer, and wherein the one or more further therapeutic agents are gemcitabine and carboplatin.

11. The method of claim 1 , wherein the therapeutically effective amount of an antibody or antigen-binding fragment that has binding specificity for human interleukin-1 receptor accessory protein (IL1RAP) is administered to the subject prior to the administration of the one or more further therapeutic agents.

12. The method of claim 11 , wherein the therapeutically effective amount of an antibody or antigen-binding fragment that has binding specificity for human interleukin-1 receptor accessory protein (IL1RAP) is administered to the subject

(a) prior to each treatment cycle of the one or more further therapeutic agents and/or

(b) one week prior to the first treatment cycle of the one or more further therapeutic agents.

13. The method of claim 1 , wherein the antibody or antigen-binding fragment comprises a heavy chain variable region comprising or consisting of the amino acids of SEQ ID NO: 9.

14. The method of claim 1 , wherein the antibody or antigen-binding fragment comprises a light chain variable region comprising or consisting of the amino acids of SEQ ID NO: 16.

15. The method of claim 1 , wherein the antibody or antigen-binding fragment comprises a heavy chain variable region comprising or consisting of the amino acids of SEQ ID NO: 9, and a light chain variable region comprising or consisting of the amino acids of SEQ ID NO: 16.

16. The method of claim 1 , wherein the antibody or antigen-binding fragment comprises:

a. a heavy chain variable region which comprises or consists of the amino acid sequence of SEQ ID NO: 8 and a light chain variable region which comprises or consists of the amino acid sequence of SEQ ID NO: 15;

b. a heavy chain variable region which comprises or consists of the amino acid sequence of SEQ ID NO: 9 and a light chain variable region which comprises or consists of the amino acid sequence of SEQ ID NO: 15;

c. a heavy chain variable region which comprises or consists of the amino acid sequence of SEQ ID NO: 10 and a light chain variable region which comprises or consists of the amino acid sequence of SEQ ID NO: 15;

d. a heavy chain variable region which comprises or consists of the amino acid sequence of SEQ ID NO: 11 and a light chain variable region which comprises or consists of the amino acid sequence of SEQ ID NO: 15;

e. a heavy chain variable region which comprises or consists of the amino acid sequence of SEQ ID NO: 8 and a light chain variable region which comprises or consists of the amino acid sequence of SEQ ID NO: 16;

f. a heavy chain variable region which comprises or consists of the amino acid sequence of SEQ ID NO: 9 and a light chain variable region which comprises or consists of the amino acid sequence of SEQ ID NO: 16;

g. a heavy chain variable region which comprises or consists of the amino acid sequence of SEQ ID NO: 10 and a light chain variable region which comprises or consists of the amino acid sequence of SEQ ID NO: 16;

h. a heavy chain variable region which comprises or consists of the amino acid sequence of SEQ ID NO: 11 and a light chain variable region which comprises or consists of the amino acid sequence of SEQ ID NO: 16;

i. a heavy chain variable region which comprises or consists of the amino acid sequence of SEQ ID NO: 8 and a light chain variable region which comprises or consists of the amino acid sequence of SEQ ID NO: 17;

j. a heavy chain variable region which comprises or consists of the amino acid sequence of SEQ ID NO: 9 and a light chain variable region which comprises or consists of the amino acid sequence of SEQ ID NO: 17;

k. a heavy chain variable region which comprises or consists of the amino acid sequence of SEQ ID NO: 10 and a light chain variable region which comprises or consists of the amino acid sequence of SEQ ID NO: 17; or

l. A heavy chain variable region which comprises or consists of the amino acid sequence of SEQ ID NO: 11 and a light chain variable region which comprises or consists of the amino acid sequence of SEQ ID NO: 17.

17. The method of claim 1 , wherein the antibody or antigen-binding fragment is humanized.

18. The method of claim 1 , wherein the antibody or antigen-binding fragment and/or the one or more further therapeutic agents are administered intravenously.

19. A method for prolonging survival of a cancer patient, wherein the cancer is associated with cells expressing IL1RAP the method comprising administering to the cancer patient (a) a therapeutically effective amount of an antibody that has binding specificity for human interleukin-1 receptor accessory protein (IL1RAP), and (b) one or more further therapeutic agents, thereby increasing the cancer patient's likelihood of survival as compared to a control patient who receives treatment comprising the one or more further therapeutic agents but not the antibody that has binding specificity for human interleukin-1 receptor accessory protein (IL1RAP), wherein the one or more further therapeutic agents are chemotherapeutic and/or immunotherapeutic agents, and wherein the antibody comprises:

a. A heavy chain variable region (VH) comprising (i) heavy chain CDR1 comprising GYAFTSS (amino acids 26-32 of SEQ ID NO: 9); (ii) heavy chain CDR2 comprising YPGDGN (SEQ ID NO: 4); and (iii) heavy chain CDR3 comprising GYLDPMDY (SEQ ID NO: 5); and a light chain variable region (VL) comprising (i) light chain CDR 1 comprising ASQGINNYLN (amino acids 25-34 of SEQ ID NO: 16); (ii) light chain CDR2 comprising YTSGLHA (SEQ ID NO: 13); and (iii) light chain CDR3 comprising: QQYSILPWT (SEQ ID NO: 14);

b. A heavy chain variable region (VH) comprising (i) heavy chain CDR1 comprising GYAFTSS (amino acids 26-32 of SEQ ID NO: 9); (ii) heavy chain CDR2 comprising YPGDGN (SEQ ID NO: 4); and (iii) heavy chain CDR3 comprising GYLDPMDY (SEQ ID NO: 5); and a light chain variable region (VL) comprising (i) light chain CDR 1 comprising SASQGINNYLN (SEQ ID NO: 12); light chain CDR2 comprising YTSGLHA (SEQ ID NO: 13); and (iii) light chain CDR3 comprising QQYSILPWT (SEQ ID NO: 14);

c. A heavy chain variable region (VH) comprising (i) heavy chain CDR1 comprising GYAFSSS (SEQ ID NO: 3); (ii) heavy chain CDR2 comprising YPGDGN (SEQ ID NO: 4); and (iii) heavy chain CDR3 comprising GYLDPMDY (SEQ ID NO: 5); and a light chain variable region (VL) comprising (i) light chain CDR 1 comprising SASQGINNYLN (SEQ ID NO: 12); light chain CDR2 comprising YTSGLHA (SEQ ID NO: 13); and (iii) light chain CDR3 comprising QQYSILPWT (SEQ ID NO: 14);

d. A heavy chain variable region (VH) comprising (i) heavy chain CDR1 comprising GYAFSSS (SEQ ID NO: 3); (ii) heavy chain CDR2 comprising YPGDGN (SEQ ID NO: 4); and (iii) heavy chain CDR3 comprising GYLDPMDY (SEQ ID NO: 5); and a light chain variable region (VL) comprising (i) light chain CDR 1 comprising ASQGINNYLN (amino acids 25-34 of SEQ ID NO: 16); light chain CDR2 comprising YTSGLHA (SEQ ID NO: 13); and (iii) light chain CDR3 comprising QQYSILPWT (SEQ ID NO: 14);

e. A heavy chain variable region (VH) comprising (i) heavy chain CDR1 comprising GYTFTSS (amino acids 26-32 of SEQ ID NO: 10); (ii) heavy chain CDR2 comprising YPGDGQ (amino acids 52-57 of SEQ ID NO: 10); and (iii) heavy chain CDR3 comprising GYLDPMDY (SEQ ID NO: 5); and a light chain variable region (VL) comprising (i) light chain CDR 1 comprising SASQGINNYLN (SEQ ID NO: 12); light chain CDR2 comprising YTSGLHA (SEQ ID NO: 13); and (iii) light chain CDR3 comprising QQYSILPWT (SEQ ID NO: 14); or

f. A heavy chain variable region (VH) comprising (i) heavy chain CDR1 comprising GYTFTSS (amino acids 26-32 of SEQ ID NO: 10); (ii) heavy chain CDR2 comprising YPGDGQ (amino acids 52-57 of SEQ ID NO: 10); and (iii) heavy chain CDR3 comprising GYLDPMDY (SEQ ID NO: 5); and a light chain variable region (VL) comprising (i) light chain CDR 1 comprising ASQGINNYLN (amino acids 25-34 of SEQ ID NO: 16); light chain CDR2 comprising YTSGLHA (SEQ ID NO: 13); and (iii) light chain CDR3 comprising QQYSILPWT (SEQ ID NO: 14).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2023
From: ÅGERSTAM, HELENA; FIORETOS, THOAS; JÄRÅS, MARCUS; MALMBORG HAGER, CECILIA ANN-CHRISTIN; SJÖSTRÖM, KJELL; SVEDBERG, AGNETA; VON WACHENFELDT, KARIN
To: CANTARGIA AB
Reel/Frame 062611/0380 →
Priority Claims (1)
GB 1403875 · Mar 5, 2014 · national
Continuity (6)
Continuation 16930631 · Jul 16, 2020
Continuation 16358459 · Mar 19, 2019
Continuation 15707593 · Sep 18, 2017
Division 15255585 · Sep 2, 2016
Continuation PCTGB2015050647 · Mar 5, 2015
Related Publication 20220106396A1 · Apr 7, 2022
References Cited (161)
US 4235871A · Papahadjopoulos et al. · 1980 [cited by applicant]
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 5851451A · Takechi et al. · 1998 [cited by applicant]
US 7960512B2 · Stavenhagen et al. · 2011 [cited by applicant]
US 8709715B2 · Karsunky · 2014 [cited by applicant]
US 8715619B2 · Karsunky · 2014 [cited by applicant]
US 9371390B2 · Karsunky · 2016 [cited by applicant]
US 9403906B2 · Fioretos et al. · 2016 [cited by applicant]
US 9458237B2 · Fioretos et al. · 2016 [cited by applicant]
US 10005841B2 · Fioretos et al. · 2018 [cited by applicant]
US 10005842B2 · Fioretos et al. · 2018 [cited by applicant]
US 10100119B2 · Ågerstam et al. · 2018 [cited by applicant]
US 10562971B2 · Ågerstam et al. · 2020 [cited by applicant]
US 20030215453A1 · Dedera et al. · 2003 [cited by applicant]
US 20060019256A1 · Clarke et al. · 2006 [cited by applicant]
US 20090285799A1 · Nash et al. · 2009 [cited by applicant]
US 20170121420A1 · Heidrich et al. · 2017 [cited by applicant]
US 20180293895A1 · Fioretos et al. · 2018 [cited by applicant]
US 20180334506A1 · Fioretos et al. · 2018 [cited by applicant]
US 20190338038A1 · Jiang et al. · 2019 [cited by applicant]
EP 0213303B1 · 1991 [cited by applicant]
EP 2213683B1 · 2013 [cited by applicant]
EP 2467403B1 · 2015 [cited by applicant]
EP 2665749B1 · 2016 [cited by applicant]
EP 2271673B1 · 2016 [cited by applicant]
EP 3020730B1 · 2018 [cited by applicant]
EP 3293202B1 · 2021 [cited by applicant]
WO 1996023067A1 · 1996 [cited by applicant]
WO 2005007197A3 · 2005 [cited by applicant]
WO 2009091547A1 · 2009 [cited by applicant]
WO 2009120903A9 · 2010 [cited by applicant]
WO 2011021014A3 · 2011 [cited by applicant]
WO 2012098407A1 · 2012 [cited by applicant]
WO 2012177595A1 · 2012 [cited by applicant]
WO 2013059973A1 · 2013 [cited by applicant]
WO 2014113433A1 · 2014 [cited by applicant]
WO 2015132602A1 · 2015 [cited by applicant]
WO 2016020502A1 · 2016 [cited by applicant]
WO 2016207304A2 · 2016 [cited by applicant]
WO 2017079121A2 · 2017 [cited by applicant]
WO 2018071910A2 · 2018 [cited by applicant]
Stanford University, Source Su. Host: Source Search, Dec. 31, 2009, Jun. 21, 2016. [cited by applicant]
Steurer et al., “Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance”, J Immunol 1995; 155:1165-1174. [cited by applicant]
Stewart et al.: “The role of Fc gamma receptors in the activity of immunomodulatory antibodies forcancer”, Journal of Imnno Therapy of Cancer, vol. 2, No. 29, Aug. 19, 2014. [cited by applicant]
Strohl, William R. “Optimization of Fc-mediated effector functions of monoclonal antibodies”, Current Opinion in Biotechnology 2009, 20:685-691. [cited by applicant]
Su et al. “Molecular classification of human carcinomas by use of gene expression signatures” Cancer Research 61, 7388-7393, Oct. 5, 2001. [cited by applicant]
Talantov et al. “Novel genes associated with malignant melanoma but not benign melanocytic lesions” Clin Cancer Res. 2005; 11(20) Oct. 15, 2005. [cited by applicant]
Tan et al: “DNA, RNA, and Protein Extraction: The Past and The Present”, Journal of Biomedicine andBiotechnology. vol. 2009; ID 574398. doi: 10.1155/2009/574398. [cited by applicant]
Thomas et al., “Structure of the activating IL-1 receptor signaling complex”, Nature Structural &Molecular Biology, vol. 19, No. 4, Apr. 2012. [cited by applicant]
Towne et al., “Interleukin (IL)-1F6, IL-1F8, and IL-1F9 Signal through IL-1Rrp2 and IL-1RAcP to Activatethe Pathway Leading to NF-kB and MAPK Regulation of IL-1 Responses Is Via Type I Receptor, Not theAccessory Protein… [cited by applicant]
Vaccaro et al., “Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels”, Nature Biotechnology vol. 23 No. 10 Oct. 2005, 1283-1288. [cited by applicant]
Verhoeyen et al., “Reshaping Human Antibodies: Grafting an Antilysozyme Activity”, Science, New Series, vol. 239, No. 4847 (Mar. 25, 1988), pp. 1534-1536. [cited by applicant]
Vigne et al., “IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4 T cells”, Blood, Oct. 25, 2012 vol. 120, No. 17, 3478-3487. [cited by applicant]
Visvader et al., “Cancer stem cells in solid tumours:accumulating evidence and unresolved questions”, Nature Reviews, Cancer, vol. 8, Oct. 2008, 755-768. [cited by applicant]
Von Mehren et al. “Monoclonal antibody therapy for cancer” Annu. Rev. Med. 2003, 54: 343-69. [cited by applicant]
Wang et al., “Structural insights into the assembly and activation of IL-1b with its receptors”, nature immunology vol. 11 No. 10 Oct. 2010, 905-911. [cited by applicant]
Wang et al: “Antibody Structure, Instability, and Formulation”, Journal of Pharmaceutical Sciences, vol. 96, No. 1, Jan. 2007. [cited by applicant]
Winter and Milstein, “Man-made antibodies”, Nature, vol. 349, Jan. 24, 1991, 293-299. [cited by applicant]
Yoon and Dinarello, “Antibodies to Domains II and III of the IL-1 Receptor Accessory Protein Inhibit IL-1B Activity But not Binding: Regulation of IL-1 Responses Is Via Type I Receptor, Not the Accessory Protein”, The J… [cited by applicant]
Zalevsky et al., “Enhanced antibody half-life improves in vivo activity”, nature biotechnology vol. 28 No. 2 Feb. 2010, 157-159. [cited by applicant]
Huang and Miller, “A Time-Efficient, Linear-Space Local Similarity Algorithm*”, Advances in Applied Mathematics 12, 337-357 (1991). [cited by applicant]
Huang et al., “Recruitment of IRAK to the interleukin 1 receptor complex requires interleukin 1 receptor accessory protein”, Proc. Natl. Acad. Sci. USA, vol. 94, Nov. 1997, pp. 12829-12832. [cited by applicant]
Iannello and Ahmad. “Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies” Cancer and Metastasis Reviews, 24: 487-499, 2005. [cited by applicant]
Idusogie et al., “Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc”, Immunol 2000; 164:Nov. 10, 2016, 4178-4184. [cited by applicant]
Iida et al., “Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood”, BMC Cancer, Feb. 18, 2009, 1-12. [cited by applicant]
Immunoglobulin heavy chain, partial [ [cited by applicant]
Järås et al. “Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein” PNAS, Sep. 14, 2010, vol. 107, No. 37, 16280-16285. [cited by applicant]
JC-kappa protein—human, NCBI. Genbank Accession No. S52059, 2000. [cited by applicant]
Jiang, X. et al. “Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies” Leukemia, 21:926-935 (2007). [cited by applicant]
Jones et al., “Replacing the complementarity-determining regions in a human antibodywith those from a mouse”; Nature, vol. 321, May 29, 1986, 522-525. [cited by applicant]
Juric et al. “Differential gene expression patterns and interaction networks in BCR-ABL-positive and negative adult acute lymphoblastic leukemias” J Clin Oncol, 25: 1341-1349 (2007). [cited by applicant]
Köhler et al., “Continuous cultures of fused cells secreting antibody of predefined specificity”, Nature, vol. 256, Aug. 7, 1975, 495-497. [cited by applicant]
Kozbor et al., “Specific Immunoglobulin Production and Enhanced Tumorigenicity Following Ascites Growth of Human Hybridomas”, Journal of Immunological Methods, 81 (1985) 31-42. [cited by applicant]
Krause et al., “Grafting of thrombopoietin-mimetic peptides into cystine knot miniproteins yields high-affinity thrombopoietin antagonists and agonists”, FEBS Journal 274 (2007) 86-95. [cited by applicant]
Kurtzhals et al., “Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity andtiming of the insulin effect in vivo” , Biochem. J… [cited by applicant]
Labrijn et al., “Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo”, nature biotechnology vol. 27 No. 8 Aug. 2009, 767-771. [cited by applicant]
Lazar et al., “Engineered antibody Fc variants with enhanced effector function”, PNAS Mar. 14, 2006 vol. 103 No. 11, 4005-4010. [cited by applicant]
Lingel, Andreas et al., “Structure of IL-33 and Its Interaction with the ST2 and IL-1RAcPReceptors-Insight into Heterotrimeric IL-1 Signaling Complexes”, Structure, vol. 17, Oct. 14, 2009. [cited by applicant]
Liu et al., “Structural insights into the interaction of IL-33 with its receptors”, Proceedings of the NationalAcademy of Sciences of the United States of America, vol. 110, No. 37, Sep. 10, 2013. [cited by applicant]
Luchini et al., “Protein painting reveals solvent-excluded drug targets hidden within native protein-proteininterfaces”, Nature communications, vol. 5, No. 4413, Jul. 22, 2014. [cited by applicant]
Majeti, R. et al. “CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells” Cell, 138:286-299 (2009). [cited by applicant]
Marks et al., “By-passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage”, J. Mol. Biol. (1991) 222, 581-597. [cited by applicant]
Marks et al: “By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling”, NatBiotechnol, vol. 10, 779-783 (Jul. 1992). https.,11,cloi.org/10.1038 in bt0792-7.1.9. [cited by applicant]
Mézière et al., “In vivo T helper cell response to retro-inverso peptidomimetics”, J Immunol 1997; 159:3230-3237. [cited by applicant]
NCBI, NCBI GEO Talatov. Host: NCBI Gene Expression Omnibus (GEO) database, Aug. 25, 2005, Jun. 21, 2016. [cited by applicant]
Nelson, Aaron L.: “Antibody fragments”, Hope and hype. MAbs. (2010); vol. 2, issue 1, pp. 77-83.doi:10.4161/mabs.2.1.10786. [cited by applicant]
Notice of Opposition in EP3293202 by Bluefin BioMedicine, Inc. filed on Nov. 24, 2022. [cited by applicant]
Notice of Opposition in EP3293202 by Ichnos Sciences, S.A. filed on Nov. 24, 2022. [cited by applicant]
Notice of Opposition in EP3293202 by Zwicker Schnappauf & Partner Patentanwalte PartGmbB filed on Nov. 24, 2022. [cited by applicant]
Notice of Recordation, recording assignment from Cellerant Therapeutics, Inc. to Cantargia AB for U.S. Pat. No. 8,709,715, recorded on Apr. 21, 2020 at Reel/Frame: 052454/0470. [cited by applicant]
Notice of Recordation, recording assignment from Cellerant Therapeutics, Inc. to Cantargia AB for U.S. Pat. No. 8,715,619, recorded on Apr. 21, 2020 at Reel/Frame: 052454/0472. [cited by applicant]
Notice of Recordation, recording assignment from Cellerant Therapeutics, Inc. to Cantargia AB for U.S. Pat. No. 9,371,390, recorded on Apr. 21, 2020 at Reel/Frame: 052454/0474. [cited by applicant]
Notice of Recordation, recording assignment from Cellerant Therapeutics, Inc. to Cantargia AB for U.S. Pat. No. 20190338038, recorded on Apr. 21, 2020 at Reel/Frame: 052454/0451. [cited by applicant]
Nygren, Per-Åke “Alternative binding proteins: Affibody binding proteins developed from a small three-helix bundle scaffold”, FEBS Journal 275 (2008) 2668-2676. [cited by applicant]
Okazaki et al., “Fucose Depletion from Human IgG1 Oligosaccharide Enhances Binding Enthalpy and Association Rate Between IgG1 and FcgRIIIa”, J. Mol. Biol. (2004) 336, 1239-1249. [cited by applicant]
Orlandi et al., “Cloning immunoglobulin variable domains for expression by the polymerase chain reaction”, Proc. Natl. Acad. Sci. USA, vol. 86, May 1989, pp. 3833-3837. [cited by applicant]
Osborn et al., “Pharmacokinetic and Pharmacodynamic Studies of a Human Serum Albumin-Interferon-Fusion Protein in Cynomolgus Monkeys”, The Journal of Pharmacology and Experimental Therapeutics vol. 303, No. 2, 540-548 (… [cited by applicant]
Peipp et al., “Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells”, Blood, Sep. 15, 2008, vol. 112, No. 6, 2390-2399. [cited by applicant]
Product Datasheet—Human IL-1 RAcP/IL-1 R3 APC-conjugated Antibody, Catalog No. FAB676A (R&D Systems) Feb. 6, 2018. [cited by applicant]
Richards et al., “Optimization of antibody binding to Fc;RIIa enhances macrophage phagocytosis of tumor cells”, Mol Cancer Ther 2008;7(8). Aug. 2008, 2517-2527. [cited by applicant]
Ridker et al., “Interleukin-β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)”, American Heart Journal Oct. … [cited by applicant]
Riechmann et al., “Reshaping human antibodies for therapy”, Nature, vol. 332, Mar. 24, 1988, 323-327. [cited by applicant]
Ryan et al., “Antibody targeting of B-cell maturation antigen on malignant plasma cells”, Mol Cancer Ther 2007;6(11). Nov. 2007, 3009-3018. [cited by applicant]
Schier et al.: “Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Ft/ by Molecular Evolution of theComplementarity Determining Regions in the Center of the Antibody Binding Site”, Journal of MolecularBiology, v… [cited by applicant]
Schlehuber and Skerra, “Keynote review: Lipocalins in drug discovery:from natural ligand-binding proteins to anticalins”, DDT ⋅ vol. 10, No. 1 ⋅ Jan. 2005, 23-33. [cited by applicant]
Screen shot of email chain between Ting-Lei Gu of Bluefin Biomedicine Inc. and Marissa Beck of Bio-Techne from Jun. 12-14, 2017. [cited by applicant]
Shafaqat et al., “IL-1 receptor accessory protein is essential for IL-33-induced activation of Tlymphocytes and mast cells”, PNAS, vol. 104, No. 47, 2007. [cited by applicant]
Shields et al., “High Resolution Mapping of the Binding Site on Human IgG1 for FcgRI, FcgRII, FcgRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcgR*”, The Journal of Biological Chemistry vol. 2… [cited by applicant]
Silverman et al., “Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains”, Nature Biotechnology, vol. 23 No. 12 Dec. 2005, 1556-1561. [cited by applicant]
Angov, Evelina “Codon usage: Nature's roadmap to expression and folding of proteins”, Biotechnol. J. 2011, 6, 650-659. [cited by applicant]
Arndt et al., “Protein Engineering Protocols”, Methods in Molecular Biology, 2007. [cited by applicant]
Askmyr et al., “Selective killing of candidate AML stem cells by antibody targeting of IL1RAP”, Blood, May 2, 2013 x vol. 121, No. 18 3709-3713. [cited by applicant]
Askmyr et al.: Selective killing of candidate AML stem cells by antibody targeting of IL 1RAP.Supplemental Data. Blood May 2, 2013;121(18):3709-13. doi: 10.1182/blood-2012-09-458935. [cited by applicant]
Attucci et al., “EPI-hNE4, a Proteolysis-Resistant Inhibitor of Human Neutrophil Elastase and Potential Anti- Inflammatory Drug forTreating Cystic Fibrosis”, The Journal of Pharmacology and Experimental Therapeutics vol… [cited by applicant]
Balagurunathan et al. “Gene expression progfilling based identification of cell surface targets for developing multimeric igands in pancreatic cancer” Mol Cancer Ther. Sep. 2008, 7(9): 3071-3080. [cited by applicant]
Barreyro et al., “Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDA”, Blood, Aug. 9, 2012 vol. 120, No. 6, 1290-1298. [cited by applicant]
Baudys et al., “Extending Insulin Action in Vivo by Conjugation to Carboxymethyl Dextran”, Bioconjugate Chem. 1998, 9, 176-183. [cited by applicant]
Ben-Kasus et al. “Cancer therapeutic antibodies come of age: Targeting minimal residual disease” Molecular Oncology, 1, 2007, 42-54. [cited by applicant]
Bianchetti et al: “IL-33 promotes the migration and proliferation of circulating fibrocytes from patientswith allergen-exacerbated asthma”. Biochem Biophys Res Commun, 2012;426(1):116-121. [cited by applicant]
Binz et al., “High-affinity binders selected from designed ankyrin repeat protein libraries”, Nature Biotechnology vol. 22 No. 5 May 2004, 575-582. [cited by applicant]
Boerner et al., “Production of Antigen-Specific Human Monoclonal Antibodies From in Vitro-Primed Human Splenocytes”, The Journal of Immunology, vol. 147. 86-95. No. 1. July 1. 1991, 86-95. [cited by applicant]
Bowen et al., “Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein”, Experimental Hematology 27 (1999) 425-432. [cited by applicant]
Brendel, C. and Neubauer. A., “Characteristics and analysis of normal and leukemic stem cells:current concepts and future directions” Leukemia, 14:1711-1717 (2000). [cited by applicant]
Bruhns et al., “Specificity and affinity of human Fc receptors and their polymorphic variants for human IgG subclasses”, Blood, Apr. 16, 2009 vol. 113, No. 16, 3716-3725. [cited by applicant]
Busfield et al., “Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC”, Leukemia (2014) 28, 2213-2221. [cited by applicant]
Chamat et al., “Human Monoclonal Antibodies Isolated from Spontaneous Epstein-Barr Virus-Transformed Tumors of Hu-SPL-SCID Mice and Specific for Fusion Protein Display Broad Neutralizing Activity Toward Respiratory Sync… [cited by applicant]
Chan et al., “Lowering of Trichosanthin Immunogenicity by Site-Specific Coupling to Dextran”, Biochemical Pharmacology, vol. 57, pp. 927-934, 1999. [cited by applicant]
Chapman “PEGylated antibodies and antibody fragments for improved therapy: a review” Advanced drug delivery reviews 54 (2002) 531-545. [cited by applicant]
Chapman et al., “Therapeutic antibody fragments with prolonged in vivo half-lives”, Nature Biotechnology vol. Aug. 17, 1999, 780-783. [cited by applicant]
Chowdhury et al: “Improving antibody affinity by mimicking somatic hypermutation in vitro”, NatureBiotechnology, vol. 17, pp. 568-572 (1999), https: edoi.orP/10.1038/9872. [cited by applicant]
Cole et al., “Human monoclona/antibodies”, Molecular and Cellular Biochemistry 62, 109-120 (1984), 109-120. [cited by applicant]
Consolidated list of references cited in opposition to EP3293202 dated Feb. 1, 2022. [cited by applicant]
Cote et al., “Generation of human monoclonal antibodies reactive with cellular antigens”, Proc. Nati. Acad. Sci. USA, vol. 80, Apr. 1983, pp. 2026-2030. [cited by applicant]
Data Sheet: Human IL-1 RAcP/IL-1 R3 Antibody: Monoclonal Mouse IgG1 Clone # 89412 Catalog No. MAB676. R&D Systems, Feb. 7, 2018. [cited by applicant]
Datasheet SKNO-1 cell line. Downloaded from the internet at https://www.dsmz.de/collection/catalogue/details/culture/ACC-690 on Nov. 18, 2021. [cited by applicant]
Datta-Mannan et al., “Humanized IgG1 Variants with Differential Binding Properties to the Neonatal Fc Receptor: Relationship to Pharmacokinetics in Mice and Primates”, Drug Metabolism and Disposition vol. 35, No. 1, DMD… [cited by applicant]
Declaration by Dr. John C. Matese, Jun. 21, 2016. [cited by applicant]
Diehn et al. “SOURCE: a unified genomic resource of funtional annotations, ontologies, and gene expression data” Nucleic Acids Research, 2003, vol. 31, No. 1. [cited by applicant]
Dinarello, Charles A. “Biologic Basis for Interleukin-I in Disease”, Blood, vol. 87, No. 6 (Mar. 15, 1996),: pp. 2095-2147. [cited by applicant]
Dinarello, Charles A. “Impact of basic research on tomorrow's medicine”, CHEST / 118 / 2 / Aug. 2000 503-508. [cited by applicant]
Dinarello, Charles Anthony “An Expanding Role for Interleukin-1 Blockade from Gout to Cancer”, Mol Med 20 (Supplemental 1), S43-S58, 2014. [cited by applicant]
Edelman et al., “The Covalent Structure of an Entire TG Immunoglobulin Molecule*”, vol. 63, 1969, Biochemistry,78-85. [cited by applicant]
Elliott et al., “Enhancement of therapeutic protein in vivo activities through glycoengineering”, nature biotechnology, vol. 21, Apr. 2003, 414-421. [cited by applicant]
EP Application No. 15714603.6 filed on Mar. 5, 2015. [cited by applicant]
EP Application No. 17185792.3 filed on Mar. 5, 2015. [cited by applicant]
Experimental Report—Annex to the Notice of Opposition against EP3293202B1 by Ichnos Sciences, SA, Nov. 24, 2021. [cited by applicant]
First Examination Report issued in Indian Application No. 201617033067 on Apr. 6, 2021. [cited by applicant]
Frenzel et al: “Expression of Recombinant Antibodies”, Front Immunol. 2013; 4: 217. Publishedonline Jul. 29, 2013. doi: 10.3389/fimmu.2013.00217. [cited by applicant]
Gal, H. et al. “Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells” Leukemia, 20:2147-2154 (2006). [cited by applicant]
Garlanda et al., “The Interleukin-1 Family: Back to the Future”, Immunity 39, Dec. 12, 2013, 1003-1018. [cited by applicant]
GB Application No. 201403875.6 filed on Mar. 5, 2014. [cited by applicant]
Gebauer et al., “Engineered protein scaffolds as next-generation antibody therapeutics”, Current Opinion in Chemical Biology 2009, 13:245-255. [cited by applicant]
GeneCards information IL1RAP gene. Retreived from the internet at: https://genecards.org/cgi-bin/carddisp.pl?gene=IL 1RAP&keywords+human,il1rap on Nov. 18, 2021. [cited by applicant]
Goldenberg, Marvin M. “Etanercept, a Novel Drug for the Treatment of Patients with Severe, Active Rheumatoid Arthritis”, Clinical Therapeuticsvvol. 21, No. 1, 1999, 75-87. [cited by applicant]
Green and Sambrook., “Molecular Cloning, A Laboratory Manual”, Fourth Edition, vol. 1, 2012. [cited by applicant]
Hamilton-Wessler et al., “Mechanism of protracted metabolic effects of fatty acid acylated insulin, NN304, in dogs: retention of NN304 by albumin”, Diabetologia (1999) 42: 1254-1263. [cited by applicant]
Hey et al., “Artificial, non-antibody binding proteins for pharmaceutical and industrial applications”, TRENDS in Biotechnology vol. 23 No. 10 Oct. 2005, 514-522. [cited by applicant]
Hinton et al., “Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates”, The Journal of Biological Chemistry, vol. 279, No. 8, Issue of Feb. 20, pp. 6213-6216, 2004. [cited by applicant]
Hoogenboom and Winter, “By-passing Immunisation Human Antibodies from Synthetic Repertoires of Germline VH Gene Segments Rearranged in Vitro”, J. Mol. Hid. (1992) 227. 381-:388. [cited by applicant]
Cohen et al, “Safety, tolerability, and efficacy of nadunolimab in combination with pembrolizumab in patients with solid tumors”, Division of Hematology-Oncology, ESMO-poster_2024, 1 page. [cited by applicant]
Van Cutsem et al., “Efficacy and safety of the anti-IL1RAP antibody nadunolimab (CAN04) in combination with gemcitabine and nab-paclitaxel in patients with advanced/metastatic pancreatic cancer”, 2024, Clin Cancer Res 2… [cited by applicant]